NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
Awarded by NHS England · to Biogen · 2025-07-01T00:00:00+01:00 · £986,282,758
Description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. …
- Supplier
- Biogen
- Buyer
- NHS England
- Value
- £986,282,758
- Category (CPV)
- Pharmaceutical products
- Award date
- 2025-07-01T00:00:00+01:00
- Buyer constituency
- runcorn-and-helsby
Full CPV hierarchy, related awards from the same supplier and buyer, and any declared MP interest overlaps load below when JavaScript is enabled.